Background: The main goal of cervical screening programs is to detect and treat precancer before cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer. However, reports of rare HPV-negative, cytology-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs. Methods: We quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente Northern California (KPNC), where 1 208 710 women age 30 years and older have undergone triennial cervical cotesting since 2003. Screening histories preceding cervical cancers (n ¼ 623) and precancers (n ¼ 5369) were examined to assess the relative contribution of the cytology and HPV test components in identifying cases. The performances of HPV testing and cytology were compared using contingency table methods, general estimating equation models, and nonparametric statistics; all statistical tests were two-sided. Results: HPV testing identified more women subsequently diagnosed with cancer (P < .001) and precancer (P < .001) than cytology. HPV testing was statistically significantly more likely to be positive for cancer at any time point (P < .001), except within 12 months (P ¼ .10). HPV-negative/cytology-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%); these cancers were more likely to be regional or distant stage with squamous histopathology than other cases. Given the rarity of cancers among screened women, the contribution of cytology to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67.9%) of women found to have cancer during 10 years of follow-up at KPNC were detected by the first cotest performed. Conclusions: The added sensitivity of cotesting vs HPV alone for detection of treatable cancer affected extremely few women.
of precancers (2) (3) (4) (5) (6) (7) . Thus, if a single screening method were chosen to complement HPV vaccination, primary HPV testing likely would gradually supplant cytology (8) . In the United States, interim guidance issued by a committee of experts from several clinical societies recommended primary HPV testing every three years, the same as cytology (9) . Alternatively, current guidelines recommend performing both HPV testing and cytology ("cotesting"), but, in recognition of the additional reassurance provided by this approach compared with cytology alone, the screening interval is extended to every five years (10) . Draft guidelines from the US Preventive Services Task Force recently recommended either primary HPV testing every five years or cytology every three years for women age 30 to 64 years, and did not recommend cotesting.
Internationally, primary HPV testing at extended intervals (eg, every five or more years) has received more consideration than cotesting (11) (12) (13) (14) . In the United States, however, some screening authorities recommend cotesting at three-year intervals, even more often than the national guidelines, in order to match or exceed the safety achievable at considerable effort by yearly high-quality cytology (11) . Also in advocating cotesting, recent well-publicized reports have elicited concern about the safety of HPV testing alone, suggesting in particular that cytology can detect already-invasive cancers missed by HPV tests (15) (16) (17) . The existence of these cases, though very rare, is very influential in shaping screening policy.
Any confusion in an important public health practice like cervical screening is unhelpful and must be addressed. The accumulated evidence supports inclusion of HPV testing in screening; thus, the main choice moving forward is between cotesting and primary HPV testing alone. Realistic performance data are needed that quantify the additional benefit of the cytology component of cotesting as the costs of intensive screening of all women using two screening tests are substantial.
There is some urgency to deciding how to proceed. Farreaching decisions regarding cervical screening policy are being made in the coming year or two in the United States and internationally. As mentioned, the US Preventive Services Task Force is re-evaluating cervical screening methods and strategies (18) . Independently, planning for the next round of multi-organizational clinical guidelines is underway (19) .
The most extensive source of data in the United States regarding cervical cotesting comes from Kaiser Permanente Northern California (KPNC). In January 2003, just prior to US Food and Drug Administration approval of HPV and cytology cotesting in mid-2003 (20) and interim guidelines (21) in 2004, KPNC, a large integrated health care organization, introduced three-year cotesting in women age 30 years and older. KPNC has now screened more than a million women by cotesting. To our knowledge, this remains the most extensive experience of HPV testing incorporated into routine screening in the world.
To inform guidelines development and support dissemination of an optimal strategy, we have analyzed cotesting data from the KPNC program. Specifically, we wished to quantify the relative contributions of the cytology and HPV test components of cotesting in the detection of cervical precancer and cancer to help guidelines groups judge whether cotesting, and the attendant cost of dual assays, should be recommended.
Methods

Population
The KPNC population evaluated here has been described previously (22 
Screening and Clinical Management
Per KPNC clinical guidelines, women who cotested HPV negative and cytology negative (HPV-/cytology-) were offered screening again in three years (in contrast to five years in the national guidelines). Positive cotest results were managed according to internal Kaiser guidelines (23) , which were broadly concordant with national standards at the time (21, (24) (25) (26) . Women with definite cytologic abnormalities were referred to colposcopy (25) (26) (27) . Accelerated retesting at one year was performed for those women with HPV-positive/cytology-negative (HPVþ/cytology-) or HPV-negative/cytology-equivocal (HPV-/ASC-US) results; the details evolved over time as previously described (22) .
Statistical Analyses
Using the medical records, 907 cervical cancers were identified. We excluded 55 cases (6.1%) diagnosed in women younger than age 30 years because cotesting was not routinely performed in this age group, and 229 cases (25.2%) because they did not have a cotesting result prior to diagnosis and thereby could not answer the questions that we were asking. As result of these exclusions, there were 623 cervical cancers with at least one cotest up to the date of diagnosis ("prediagnostic" cotests) (28) . There was no difference in the distribution of diagnostic categories between cancers included in and excluded from these analyses (P ¼ .65).
We included for comparison all 5369 precancers, including 4929 cervical intraepithelial neoplasia grade 3 (CIN3) and 440 adenocarcinoma in situ (AIS), diagnosed in women age 30 years and older during this same period when the cancers were diagnosed. We compared HPV, cytology, and cotesting performance of all prediagnostic cotests for cancer, overall and by cancer diagnostic category (ie, SCC, ADC, microinvasive, or other cancers) and stage. The positivity of a screening test prior to diagnosis can be thought of as a kind of prognostic sensitivity. We performed a similar analysis for precancer diagnoses, overall and by diagnostic category (ie, CIN3 or AIS).
We repeated these analyses stratified for cotests obtained less than 12 vs 12 or more months prior to diagnosis; the examination of cotests taken less than 12 months prior to cancer diagnosis was undertaken in response to recent reports regarding suboptimal HPV test performance in detecting already prevalent invasive cancers (15) (16) (17) . We compared HPV and cytology cotesting results by time intervals for all cancers and for SCC and ADC separately, and for all precancers and for CIN3 and AIS separately. We also compared the cotesting results by whether the last round of cotesting prior to diagnosis was the first, second, or third (or subsequent) cotest performed at KPNC prior to diagnosis.
Women could contribute multiple cotests during any period of time. Raw numbers and percentages are presented. General estimating equation (GEE) P values were calculated using Z scores from GEE parameter estimates and empirical standard error estimates. Results using GEE were largely similar to raw values except for cells with small numbers of women (data not shown); when cells contained zero counts, McNemar P values were used. Trend tests for HPVþ, Cytoþ, and HPVþ/Cyto-vs HPV-/Cytoþ by increasing cancer stage were calculated.
In the Supplementary Tables (available online) , the P values were derived from the exact Pearson chi-square test for the frequencies (stage and race) and Kruskal-Wallis for the summary statistics (number of cotests, time from cotests, and ages). All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant.
Results
Characteristics of Cases
Characteristics of the 623 women diagnosed with cancer are shown in Supplementary Table 1 (available online) and 5369 women diagnosed with precancer are shown in Supplementary Table 2 (available online). Among those with cancer, women diagnosed with other cancers were older (median age ¼ 57 years) and those diagnosed with microinvasive cancer were younger (median age ¼ 40 years) than those diagnosed with SCC (median age ¼ 47 years) and ADC (median age ¼ 47 years; P ¼ .001, Kruskal-Wallis). By comparison, women diagnosed with precancer had a median age of 38 years (of note, this analysis excluded women younger than 30 years of age, elevating the average age of precancer).
Cotesting History Prior to Cancer Diagnoses, Evaluating the Contribution of Cytology vs HPV Testing
Paired HPV and cytology testing results (n ¼ 1137) are shown for all cotests preceding the diagnosis of cancer in 623 women (Table 1) . Overall, prediagnostic HPV testing (76.7%) was more likely to be positive (ie, was more clinically sensitive) than cytology (59.1%, P < .001 for paired comparison); 82.6% of all prediagnostic cotests were positive by HPV and/or cytology; 5.9% of the cotests were positive by cytology alone (HPV negative). Stratified on histopathology, the differences in positivity between HPV and cytology antecedent to SCC were less pronounced (75.0% vs 69.6%, respectively, P ¼ .03) than for ADC (79.0% vs 45.4%, respectively, P < .001).
Paired HPV and cytology testing results (n ¼ 10 999) are shown for all cotests preceding the diagnosis of precancer in 5369 women (Table 2) . Overall, prediagnostic HPV testing (83.8%) was more likely to be positive than cytology (61.9%, P < .001); 87.3% of prediagnostic cotests were positive by HPV and/or cytology; 3.5% of the cotests were positive by cytology alone (HPV negative). HPV testing was more likely to be positive than cytology prior to both CIN3 (83.9% vs 62.8%, P < .001) and AIS (82.2% vs 53.2%, P < .001). Table 3 shows the timing of the cotest and follow-up screening intervals relative to time of cancer (Table 3 ) and precancer diagnoses (Table 4) . Cotests done within 12 months of diagnosis were more likely to be HPV and/or cytology positive than cotests done 12 months or longer before the diagnosis. HPV was statistically significantly more likely to be positive than cytology less than 12 months prior to a precancer diagnosis (96.2% vs 89.8%, respectively, P < .001) but not immediately prior to a cancer diagnosis (89.2% vs 86.3%, P ¼ .1). By comparison, HPV was statistically significantly more likely to be positive than cytology 12 or more months before both a precancer diagnosis (70.6% vs 32.4%, respectively, P < .001) and a cancer diagnosis (62.8% vs 28.7%, P < .001).
The percentages of the results for paired HPV and cytology cotesting by time interval prior to diagnosis for both precancers 
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and cancers, overall and by main histology types, are shown in Figure 1 . Women diagnosed with precancer or cancer were more likely to test HPV positive than cytology positive at any time interval prior to diagnosis. A positive cotest was only very slightly more likely (absolute, not relative, increase) for precancers (as a percentage of the total cotested precancer population) and for cancers than testing HPV positive alone at any time interval prior to diagnosis.
Cotesting Screening History Prior to Precancer vs Cancer Diagnoses
As shown in Table 4 , the last cotest prior to diagnosis (median ¼ 0.15 years, mean ¼ 0.42 years, interquartile range ¼ 0.32-0.06 years, and range ¼ 7.25-0.00 years prior to diagnosis) was less likely to be HPV positive (P trend < .001) or cytology positive (P trend ¼ .007) with more severe stage of cancer. However, an increasing percentage was positive only by cytology (HPV negative) with more severe stage (5.1% for localized, 11.8% for regional, and 17.2% for distant spread) while the reverse was true for HPV testing (cytology negative; 10.2% for localized, 6.5% for regional, and 0.0% for distant) (P trend ¼ .002). Thus, for the last cotest prior to diagnosis, HPV testing was more sensitive for localized cancer (90.7% vs 85.6%, P ¼ .02) but was marginally less sensitive for distant cancer (51.7% vs 69.0%, P ¼ .06) compared with cytology. We estimated by review of all cancer cases with at least one preceding HPV-negative test (n ¼ 55 women) that 14 were tested at the time of colposcopy as part of the diagnostic work-up, not as part of screening. At maximum, there were 23 women whose cancers were missed by HPV in a prior screen *Some women contributed more than one cotesting result prior to diagnosis. "þ" indicates a positive result, and "-" indicates a negative result; "Anyþ" means that HPV and/or Pap were positive. AIS ¼ adenocarcinoma in situ; CIN 3 ¼ cervical intraepithelial neoplasia grade 3; Cyto ¼ cytology; HPV ¼ human papillomavirus. †Two-sided P values comparing HPV tests with cytology were based on Z scores calculated from general estimating equation parameter estimates and empirical standard error estimates.
but caught by cytology (at the definite threshold of LSIL or greater). We included in this count even those instances in which the positive cytology result would have advanced the diagnostic date by a very small amount of time, and also included those cases for which the cancer stage was distant spread at diagnosis. The same result expressed as a rate indicates that, in 2010, there were 23 additional true-positive screens per 1 618 394 women, or per 4 917 774 woman-years (3.04 years of follow-up on average per woman), that is, 4.7 per million woman-years. Table 5 addresses the relative performances of cotests when more than one was taken for a woman prior to diagnosis; most ARTICLE precancers (58.3%) and cancers (67.9%) diagnosed at KPNC were found after the first cotest was taken. HPV was more likely than cytology to test positive on the first, second, and third or subsequent cotests prior to a precancer diagnosis (P < .001 for all comparisons) and on the first (P < .001), second (P ¼ .02), and third or subsequent cotests (P < .001) prior to a cancer diagnosis. The sensitivity of cotesting for diagnosis of cancer declined from the first cotest to the second and third or subsequent cotests prior to the cancer diagnosis (5.7%, 13.0%, and 12.9% negative cotests, respectively). Moreover, the cotesting results were less likely to be positive prior to a cancer diagnosis compared with a precancer diagnosis (P < .001 for all comparisons).
Sequential Cotests Prior to Diagnosis
Discussion
This systematic evaluation of the very few cancers diagnosed within the first and most extensive major HPV/cytology cotesting program in the United States confirms the sensitivity advantage of HPV tests. The evaluation also demonstrates that recent reports questioning the sensitivity of HPV testing for detection of cancer were based on partial analyses with short follow-up that accentuated the role of cytology (15, 16, 29) .
Viewed more comprehensively, the contribution of the cytology component to cotesting performance is quite limited for detection of treatable precancers and early curable cancers. Warnings that reliance on primary HPV testing would encourage cervical cancer mortality are overstated (15) . To discuss in more depth the critical point of the analysis, as shown here and previously reported (30, 31) , limiting analyses of cotesting results to the year before diagnosis reveals increased test positivity for HPV but even more so for cytology (perhaps due to recognition of tumor diathesis or debris devoid of viable cells). The clinical value is uncertain; testing positive at a time in which the cancer is already present (even advanced) is not prevention and thus is not consistent with the fundamental goals of cervical cancer screening. In any case, the percentage of all cancers combined that was detected by cytology alone was about 5% of an extremely small absolute number, as previously reported from a number of trials and epidemiologic studies (23, 32, 33) .
Given that cytologic screening of the approximate 90þ% of women who are HPV negative, or repeating screening at shorter intervals, would virtually automatically produce a small increase in diagnosis of precancers and treatable cancers (23) , the question becomes what is the threshold of acceptable cancer Table 5 . Human papillomavirus and cytology cotesting results directly prior to diagnosis of cervical cancers and precancers, for first, second, and third or later cotest performed* risk, given that no reasonable approach will achieve perfect protection against cervical cancer mortality. In other words, what screening method and interval achieve the best benefits-toharms ratio and cost-effectiveness over a "lifetime" of screening. There are potential harms associated with excessive screening, including the identification and overtreatment of potentially regressive CIN2 lesions (34, 35) and possible increased risk of negative reproductive outcomes such as preterm delivery (36-39). The choice of acceptable level of safety compared with disadvantages of frequent intensive screening is not a scientific question. Rather it requires societal consensus/compromise beyond the scope of this presentation.
There were limitations of this analysis. First, we had screening data only from KPNC, a single integrated health system whose members and practices are not representative of all populations. Second, why certain tests or procedures were done at any given time was not always clear. Third, at KPNC the cotest is collected as two separate specimens, with the HPV tests being collected right after the cytologic specimen, which may have reduced the HPV testing performance compared with primary HPV testing or cospecimen collection of both specimens in a single cell collection.
With regard to strengths of this work, we were able to examine the long-term relative history of HPV tests and cytology prior to cancer diagnosis. We could show that the results of previous analyses are at least in part the result of design decisions leading to bias. Restriction to cases occurring within one year of screening tests biases against the use of HPV testing because HPV-positive, cytology-negative results lead to recommendations of return in one year. Any cancer cases diagnosed among women who return even slightly late are missed in the analysis, making HPV testing appear to be less sensitive than it is. The goal of screening is to diagnose precancers and treatable cancers as early as possible (40, 41) , certainly more than a year before diagnosis of regional or distant stage invasive disease. When properly examined over the long term, the contribution of cytology to screening is shown to be very small, and the need for continued rounds of cotesting is worth questioning. Others have suggested that a hybrid strategy might be to start with cotesting for women with unknown screening histories and then switch to primary HPV testing after one or two negative cotests (42, 43) . The trade-offs in benefits and harms as well as the cost-effectiveness of such a complex strategy will need to be evaluated, and its implementation may pose some practical challenges.
It is possible that screening intrinsically worked less well for those few women who developed cancer vs those who were diagnosed with precancer. Women diagnosed with cancer were less likely to test HPV positive and/or cytology positive than those diagnosed with precancer, overall, at any time point, or for any round of cotesting. Indeed, comparing cotesting results prior to a precancer diagnosis with results five years prior to a cancer diagnosis (when the latter might still have been precancer), raise the question of inherently less effective screening efficacy in women developing cancer.
The introduction of HPV testing alone as a cervical cancer screening option would perform nearly the same as HPV and cytology cotesting (44) . The choice between the two strategies and the screening interval chosen, whether three years or five years or more, depends on societal judgments (eg, cancer prevention benefits vs resource allocation) and not scientific facts. Nevertheless, even using cotesting at three-year intervals (the most aggressive strategy in common use), cervical cancer continues to occur rarely (albeit typically at a curable stage).
Excessive screening in an attempt to prevent every case could have minimal cancer prevention benefits while increasing the harms of screening. 
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